Latest Production Development News

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Aerometrex’s flagship platform MetroMap has reached a significant milestone, surpassing $10 million in Annual Contract Value, reflecting strong growth and customer trust since its 2020 launch.

Nufarm Limited reported a 3% revenue increase to $1.81 billion for the half-year ended March 2025, driven by Crop Protection volume growth. However, net profit after tax fell 39% amid fish oil pricing pressures and higher operating costs, prompting the board to withhold an interim dividend.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Green360 Technologies has successfully produced high-quality metakaolin from its kaolin resources, surpassing industry benchmarks and initiating commercial-scale trials with PERMAcast to validate its low-carbon cement formulations.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Gentrack Group Limited reported a solid 9.8% revenue increase to NZ$112 million in the first half of FY25, powered by strong recurring revenue growth in utilities and a surge in its airports division, Veovo. Net profit after tax jumped 34.7%, supported by currency gains and a lower tax rate.

Gentrack Group Ltd reported a robust 9.8% revenue increase and a 34.7% jump in net profit for the first half of FY25, driven by strong recurring revenues and strategic global expansion.